Multiple Agents Prove Useful in RET-Mutated Thyroid Cancer
June 24th 2021Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.
Roundtable Discussion: Fonseca Compares Frontline Therapy in Newly Diagnosed Multiple Myeloma
June 1st 2021Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.
Roundtable Discussion: Dingli Discusses Treatment Options in Transplant-Eligible Multiple Myeloma
May 28th 2021David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, discussed the treatment options available for patients with transplant-eligible multiple myeloma with a group of peers during a Targeted Oncology Case-Based Roundtable event.
Roundtable Discussion: Exploring Factors of a Patient With RR-DTC to Decide Appropriate Treatment
May 23rd 2021Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.
Carducci Discusses CARD Trial Data for Metastatic Castration-Resistant Prostate Cancer
May 12th 2021During a virtual Targeted Oncology Case-Based Roundtable event, Michael A. Carducci, MD, reviewed the results of the CARD trial to support his recommendation of cabazitaxel for the treatment of a 75-year-old man with metastatic castration-resistant prostate cancer.
Talazoparib May Be Most Optimal for Patients with Germline or Homozygous tDDR-altered mCRPC
May 9th 2021According to findings from a subgroup analysis of the TALAPRO-1 trial, men with heavily pretreated metastatic castration-resistant prostate cancer, with germline and/or homozygous tumor DNA damage response alterations are most likely to respond to talazoparib.